榮昌生物(09995.HK):泰它西普治療系統性紅斑狼瘡由附條件批准轉為完全批准
榮昌生物(09995.HK)公布,泰它西普,商品名為泰愛,正式獲得國家藥監局同意,由附條件批准轉為完全批准,用於與常規治療聯合,針對在常規治療基礎上仍具有高疾病活動性、自身抗體陽性的系統性紅斑狼瘡成年患者。
集團指,此次獲完全批准也是該藥物繼2021年首次獲附條件批准、成功納入2022版國家醫保藥品目錄後的又一重要進展,將進一步加速惠及更廣泛的中國系統性紅斑狼瘡患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.